Where Will Mersana Therapeutics Inc (MRSN) Stock Go Next After It Has Gained 7.69% in a Week?

Mersana Therapeutics Inc (MRSN) stock is higher by 7.69% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Mersana Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MRSN!

See Full MRSN Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With MRSN Stock Today?

Mersana Therapeutics Inc (MRSN) stock is down -3.72% while the S&P 500 has risen 1.8% as of 4:00 PM on Monday, May 23. MRSN is down -$0.13 from the previous closing price of $3.49 on volume of 682,610 shares. Over the past year the S&P 500 has fallen -5.37% while MRSN is down -76.49%. MRSN lost -$2.49 per share in the over the last 12 months. To screen for more stocks like Mersana Therapeutics Inc click here.

More About Mersana Therapeutics Inc

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.